X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

100% Renewable Electricity Record Hit By Charles River Labs

Content Team by Content Team
17th May 2024
in Facilities & Operation, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Pharmaceutical and microbial testing company- Charles River Laboratories happens to be now operating all of its international branches with completely 100% renewable electricity as of Q1 of 2024.

It is worth noting that the UK-based company went on to reach this sustainability milestone quite ahead of its set date. Apparently, in 2020, Charles River went on to become one of the first 200 members of RE100, which happens to be an initiative of global corporate renewable energy.

As part of this initiative, Charles River went on to commit to functioning on 100% renewable electricity across the world by 2030. With the feat that Charles River has gone on to achieve that stands in sync with the RE100’s standardized reporting criteria, it has now joined a small group of companies.

In order to achieve this green goal as far as renewable electricity is concerned, the company had to make the following efforts:

It went ahead and executed two crucial virtual power purchase agreements in Europe as well as the US.

In 2020, it went on to initiate a 15-year contract with Derive Energy for a 102 MW solar vPPA that is based in Texas, which, as of January 2023, has gone on to offer 100% of the company’s North American electric power needs with clean and renewable energy.

Also in 2023, the company’s 12-year-old, 30-MW wind power vPPA went on to become live which happens to be a partnership with Repsol, which is based out of Spain and is a multi-energy company. This output goes on to cover Charles River’s overall European electricity load.

It has also collaborated with leading organizations in order to drive the adoption of green energy solutions.

In 2022, Charles River went on to get recognized by the US Environmental Protection Agency’s Green Power Partnership as the leader as far as green electricity use is concerned. In 2023, the company, as a matter of fact, joined the Renewable Thermal Collaborative, which is a global coalition of companies, governments, and institutions aimed at scaling up renewable energy when it comes to heating and cooling.

Charles River, in addition to this, also went on to sponsor Energise, which is a programme that is powered by Schneider Electric so as to amp-up the increased access to renewable energy when it comes to pharmaceutical supply chains.

The company has gone on to invest USD 13.5 million in sustainability-centric projects by way of Charles River Sustainability Capital Fund.

Right from 2020-2023, over a period of 3 years, Charles River has gone ahead and funded more than 100 projects across the world that decrease its environmental footprint and have moved towards energy conservation as well as GHG reduction.

GHG emissions are being reduced from its facilities prominently

As of 2023 end, Charles River attained a 37% in GHG emissions- Scope 1 & Scope 2 from its facilities.

Due to an increase to 100% renewable electricity in 2024, the company is now aiming for a 45% decrease by year-end, thereby making significant progress towards its objective of a 50% decrease by 2030. The chairman, president and CEO of Charles River, James Foster, remarked that in their company they happen to be guided by their need to create healthier lives, which, as a matter of fact, goes beyond science since healthy life begins with a healthy planet. He added that the announcement that has taken place indeed marks a milestone as far as their commitment to supporting sustainable business practices is concerned and is driving a marked change for their partners, clients, communities, and, of course, the planet.

Previous Post

All Infinity Laboratories Locations Are Now ISO-Accredited

Next Post

AI-Role In Supply Chain Management In Bio, Pharma Sectors

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post

AI-Role In Supply Chain Management In Bio, Pharma Sectors

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In